Sphingolipids　are　a　class　of　lipids　with　high　structural　diversity　and　biological　pleiotropy.　Mounting　evidence　supports　a　role　for　sphingolipids　in　regulating　pathophysiology　of　cardiometabolic　diseases,　and　they　have　been　proposed　as　potential　cardiometabolic　biomarkers.　Current　methods　for　quantifying　sphingolipids　require　laborious　pretreatment　and　relatively　large　sample　volumes,　and　cover　limited　species,　hindering　their　application　in　epidemiological　studies.　Herein,　we　applied　a　time-,　labor-,　and　sample-saving　protocol　simply　using　methanol　for　plasma　sphingolipid　extraction.　It　was　compared　with　classical　liquid-liquid　extraction　methods　and　showed　significant　advantages　in　terms　of　simplicity,　sphingolipid　coverage,　and　sample　volume.　By　coupling　the　protocol　with　liquid　chromatography　using　a　wide-span　mobile　phase　polarity　parameter　and　tandem　mass　spectrometry　operated　in　dynamic　multiple　reaction　monitoring　mode,　37　sphingolipids　from　8　classes　(sphingoid　base,　sphingoid　base　phosphate,　ceramide-1-phosphate,　lactosylceramide,　hexosylceramide,　sphingomyelin,　ceramide,　and　dihydroceramide)　were　quantified　within　16　min,　using　only　10　mu　L　of　human　plasma.　The　current　method　showed　good　performance　in　terms　of　linearity　(R-2　＞　0.99),　intra-　and　interbatch　accuracy　(70-123%)　and　precision　(RSD　＜　12%),　matrix　effect　(91-121%),　recovery　(96-101%),　analyte　chemical　stability　(deviation　＜　19%),　and　carryover　(＜　16%).　We　successfully　applied　this　method　to　quantify　33　detectable　sphingolipids　from　579　plasma　samples　of　an　epidemiological　study　within　10　days.　The　quantified　sphingolipid　concentrations　were　comparable　with　previous　studies.　Positive　associations　of　ceramide　C22:0/C24:0　and　their　precursors　with　homeostasis　model　assessment　of　insulin　resistance　suggested　that　the　synthesis　of　the　ceramides　might　be　involved　in　insulin　resistance.　This　novel　method　constitutes　a　simple　and　rapid　approach　to　quantify　circulating　sphingolipids　for　epidemiological　studies　using　targeted　lipidomic　analysis,　which　will　help　elucidate　the　sphingolipid-regulated　pathways　underlying　cardiometabolic　diseases.